Training of next generation of European glioblastoma (translational) researchers, to resolve precision targeting of the brain tumour microenvironment

The project aims to establish a training programme to better understand the isocitrate deshydrogenase wild-type (IDHwt) glioblastoma, the most frequent and aggressive adult brain tumours characterized by a strong immunosuppressed tumour microenvironment (TME). This will include the elucidation and dissection of distinct TME subclasses for deciphering new or improved TME targeting therapies, defining new predictive biomarkers and identifying novel subtype of specific targets.
The Norlux laboratory will apply patient-derived cancer models (primary 3D stem-like cultures, tumour 3D organoids, and patient-derived orthotopic xenografts) to interrogate tumour-stroma interactions and test cellular therapies. The project will involve several technology platforms at LIH (Norlux biobank, animal facility, MRI, LuxGen, and NCP), as well as collaborations with the LNS’s National Center of Genetics (D. Stieber and B. Klink) and the Translational Research Unit at the Oslo University Hospital. This is a follow-up of the recently completed MSCA GLIOTRAIN training programme in which the Norlux team participated.